A Phase II placebo-controlled clinical trial tested the potential utility of the methylthioninium moiety (MT) as monotherapy in mild to moderate AD in patients not taking cholinesterase inhibitors or memantine. The gene discussed is BCHE; the disease is Alzheimer disease.